pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression

BACKGROUND: Our previous study has demonstrated that knockdown of activated ERK1/2(pERK1/2) sensitizes pancreatic cancer cells to chemotherapeutic drug gemcitabine (Gem) treatment. However, the details of this survival mechanism remain undefined. It has also shown that Bcl-2 confers resistance and B...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Min, Lu, Xingjiao, Dong, Xueguang, Hao, Fengyun, Liu, Zimin, Ni, Guangzhen, Chen, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337256/
https://www.ncbi.nlm.nih.gov/pubmed/25880226
http://dx.doi.org/10.1186/s12957-015-0451-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337256/
https://www.ncbi.nlm.nih.gov/pubmed/25880226
http://dx.doi.org/10.1186/s12957-015-0451-7

Ejemplares similares